Abstract
Post-COVID-19 pulmonary fibrosis (PC19-PF) is one of the severe manifestations of the “long COVID syndrome,” with a prevalence of about 7%, and is characterized by the presence of persistent fibrotic lung changes (on a CT scan of the lungs) associated with impairment of pulmonary function. Some of the risk factors for PC19-PF include advanced age, the occurrence of acute respiratory distress syndrome (ARDS), the need for supplemental oxygen, mechanical ventilation, smoking, etc. Antifibrotic agents, e.g., pirfenidone and nintedanib, are increasingly being used in the management of PC19-PF with good outcomes, but larger studies on efficacy and benefit are needed. In this study, we present the case of a young woman in a rural Kenyan hospital found to have end-stage PC19-PF needing long-term oxygen therapy to highlight the reality of PC19-PF in the post-COVID-19 clinical era.
Keywords
post-COVID-19 pulmonary fibrosislong COVID syndromepirfenidonenintedanibcor pulmonalelong-term oxygen therapyKenya
References
- Davis, H.E., et al., Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol, 2023. 21(3): p. 133-146.Google Scholar ↗
- Chen, C., et al., Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis, 2022. 226(9): p. 1593-1607.Google Scholar ↗
- Alrajhi, N.N., Post-COVID-19 pulmonary fibrosis: An ongoing concern. Ann Thorac Med, 2023. 18(4): p. 173-181.Google Scholar ↗
- Tanni, S.E., et al., Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med, 2021. 15(6): p. 791-803.Google Scholar ↗
- Groff, D., et al., Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw Open, 2021. 4(10): p. e2128568.Google Scholar ↗
- Ojo, A.S., et al., Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. Pulm Med, 2020. 2020: p. 6175964.Google Scholar ↗
- Mehta, P., et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020. 395(10229): p. 1033-1034.Google Scholar ↗
- Wilson, M.S. and T.A. Wynn, Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol, 2009. 2(2): p. 103-21.Google Scholar ↗
- Duong-Quy, S., et al., Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review. Pulm Ther, 2023. 9(3): p. 295-307.Google Scholar ↗
- Mylvaganam, R.J., et al., Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. Eur Respir Rev, 2021. 30(162).Google Scholar ↗
- Solomon, J.J., et al., CT of Post-Acute Lung Complications of COVID-19. Radiology, 2021. 301(2): p. E383-e395.Google Scholar ↗
- Choudhary, R., et al., Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study. Cureus, 2022. 14(9): p. e29435.Google Scholar ↗
- Cojocaru, E., et al., Perspectives on Post-COVID-19 Pulmonary Fibrosis Treatment. J Pers Med, 2023. 14(1).Google Scholar ↗
- Mohammadi, A., et al., Post-COVID-19 Pulmonary Fibrosis. Cureus, 2022. 14(3): p. e22770.Google Scholar ↗
- Bharat, A., et al., Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med, 2021. 9(5): p. 487-497.Google Scholar ↗
- Patrucco, F., et al., Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks. Microorganisms, 2023. 11(4).Google Scholar ↗
- Montazersaheb, S., et al., COVID-19 infection: an overview on cytokine storm and related interventions. Virol J, 2022. 19(1): p. 92.Google Scholar ↗
- Kim, B.-G., et al., Risk of newly diagnosed interstitial lung disease after COVID-19 and impact of vaccination: a nationwide population-based cohort study. Frontiers in Public Health, 2024. 11.Google Scholar ↗
- Dhooria, S., et al., A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis, 2020. 37(2): p. 148-157.Google Scholar ↗
- Song, M.J., et al., Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital. Sci Rep, 2020. 10(1): p. 21218.Google Scholar ↗
- Al-Kuraishy, H.M., et al., Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology, 2022. 30(6): p. 2017-2026.Google Scholar ↗
- Humbert, M., et al., 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 2023. 61(1).Google Scholar ↗